N-of-1 Trial: Actionable Target Identification in Metastatic Cancer for Palliative Systemic Therapy
Status:
Completed
Trial end date:
2018-08-01
Target enrollment:
Participant gender:
Summary
The metastatic lesions may be very different from the primary tumor because of intrinsic
tumor heterogenity, clonal selection through metastatic process and following previous
cytotoxic treatments. Metastatic tumor harboring actionable targets or signaling pathways may
respond to inhibitory agents directed against specific aberrations irrespective of tumor
origin. In the MetAction study, patients will receive therapy based on molecular aberrations
in the metastatic lesions, actionable target identification (ATI), rather than on
histological tumor type.
The ATI rate in an unselected metastatic patient population is uncertain, and response rates
associated with ATI based targeted therapy have hardly been reported. In this perspective,
The MetAction study is essentially a feasibility study aiming to tailor metastatic cancer
therapy based on genomic profiles.